Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient
- 31 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (8), 2261-2274
- https://doi.org/10.1007/s00262-021-02848-0
Abstract
High expression of PD-L1 predicts PD-1/PD-L1 inhibitor benefit, meanwhile a few PD-L1-negative patients still benefit from these drugs. In this study, we aimed to explore the underlying cellular and molecular characteristics via single-cell sequencing. Before and after treatment with Pembrolizumab, peripheral blood mononuclear cells (PBMCs) were isolated via Ficoll gradient. Thereafter, single-cell RNA sequencing was performed, and clinical significance was validated with The Cancer Genome Atlas (TCGA) cohort. All 3423 cells of 16 clusters were classified into eight cell types, including NKG7+ T, NKG7+ NK, Naive T, CDC1C+ dendritic cells, CD8+ T cells, B cells, macrophages and erythrocytes. Cell proportion, the clinical significance of differentially expressed genes and significant pathways of NKG7+ T, NKG7+ NK, Naive T and CD8+ T cells were analyzed. Ubiquitin-mediated proteolysis/cell cycle/natural killer cell-mediated cytotoxicity were identified as PD-1 blockage-responsive pathways in NKG7+ NK cells. Apoptosis/Th1 and Th2 cell differentiation were proposed as Pembrolizumab-affected pathways in NKT cells. In gene level, ID2, PIK3CD, UQCR10, MATK, MZB1, IL7R and TRGC2 showed a significant correlation with PD-1 expression after TCGA dataset validation, which could possess potential as predictive markers for patients with PD-L1-negative lung squamous cell carcinoma who can benefit from Pembrolizumab.Funding Information
- Natural Science Foundation of Shanghai (19ZR1449700)
- Shanghai Chest Hospital-Collaborative Innovation Project (YJXT20190204)
This publication has 41 references indexed in Scilit:
- Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLCCancer Microenvironment, 2015
- PD-1/PD-L1 inhibitorsCurrent Opinion in Pharmacology, 2015
- Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 AntibodyCancer Research, 2014
- Data exploration, quality control and testing in single-cell qPCR-based gene expression experimentsBioinformatics, 2012
- Id2 regulates the proliferation of squamous cell carcinoma in vitro via the NF-κB/Cyclin D1 pathwayChinese Journal of Cancer, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Isolation of Whole Mononuclear Cells from Peripheral Blood and Cord BloodCurrent Protocols in Immunology, 2009
- Regulation of p27 by S-Phase Kinase-Associated Protein 2 Is Associated With Aggressiveness in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cellsProceedings of the National Academy of Sciences of the United States of America, 2003
- Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cellsCellular Immunology, 1987